Efficacy of Amphotericin B and Azoles Alone and in Combination against Disseminated Trichosporonosis in Neutropenic Mice

The activities of amphotericin B, miconazole, fluconazole, and itraconazole against Trichosporon beigelii were assessed in a mouse model of disseminated infection. Cyclophosphamide plus prednisolone-immunosuppressed ICR mice, intravenously challenged with a lethal inoculum of (6 × 106 CFU/mouse), were assigned to receive 7 days of therapy with amphotericin B (0.5 or 2 mg/kg/day), miconazole (10 or 40 mg/kg/day), fluconazole (10 or 40 mg/kg/day), or itraconazole (10 and 40 mg/kg/day). The efficacy of a combination of amphotericin B (1 mg/kg/day) with fluconazole (10 mg/kg/day) or itraconazole (20 mg/kg/day) with that of each agent alone was also compared. Both amphotericin B and azoles improved survival and reduced the fungal counts in kidneys of infected mice in a dose-dependent pattern. In general, fluconazole was superior to amphotericin B and the other azoles, whereas the latter two drugs were as effective as amphotericin B. The activity of amphotericin B combined with fluconazole appeared to be superior to that of each agent alone, especially in reducing the organ fungal burden. The other combination (amphotericin B plus itraconazole) had a weaker effect, but no antagonism was observed. In conclusion, azoles may be an alternative to amphotericin B for the treatment of T. beigelii infection. Furthermore, their combination with amphotericin B may improve the poor outcome seen in profoundly neutropenic patients with disseminated trichosporonosis.

[1]  M. Nasu,et al.  In vitro susceptibility of Trichosporon beigelii to antifungal agents. , 1996, Journal of chemotherapy.

[2]  P. Troke,et al.  Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B , 1995, Antimicrobial agents and chemotherapy.

[3]  E. Anaissie,et al.  Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis , 1994, Antimicrobial Agents and Chemotherapy.

[4]  Jackson A. Como,et al.  Oral azole drugs as systemic antifungal therapy. , 1994, The New England journal of medicine.

[5]  J. V. Etzel Oral azole drugs as systemic antifungal therapy. , 1994, The New England journal of medicine.

[6]  M. Nasu,et al.  Disseminated Trichosporon beigelii infection in patients with malignant diseases: immunohistochemical study and review. , 1994, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.

[7]  T. Patterson,et al.  Combination therapy in experimental invasive aspergillosis. , 1993, The Journal of infectious diseases.

[8]  J. Graybill,et al.  Histoplasmosis in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and fluconazole. , 1993, Journal of acquired immune deficiency syndromes.

[9]  E. Anaissie,et al.  Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  G. Lopez-Berestein,et al.  Experimental Trichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis. , 1992, The Journal of infectious diseases.

[11]  M. Saag,et al.  A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. , 1992, The New England journal of medicine.

[12]  G. Bodey,et al.  Azole antifungal agents. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  F. Gerven,et al.  Therapy of Meningeal and Disseminated Cryptococcosis , 1992 .

[14]  J. Lesher NEW ANTIFUNGAL AGENTS , 1992, Dermatologic clinics.

[15]  J. Graybill,et al.  Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination , 1991, Antimicrobial Agents and Chemotherapy.

[16]  A. Sugar Interactions of amphotericin B and SCH 39304 in the treatment of experimental murine candidiasis: lack of antagonism of a polyene-azole combination , 1991, Antimicrobial Agents and Chemotherapy.

[17]  D. Armstrong,et al.  Combination therapy in a model of pulmonary aspergillosis , 1991, Mycoses.

[18]  T. Walsh,et al.  Trichosporon beigelii, an emerging pathogen resistant to amphotericin B , 1990, Journal of clinical microbiology.

[19]  E. Anaissie,et al.  New spectrum of fungal infections in patients with cancer. , 1989, Reviews of infectious diseases.

[20]  G. Hutchins,et al.  Disseminated infection with Trichosporon beigelii. , 1987, Reviews of infectious diseases.

[21]  A. Polak Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. , 1987, Chemotherapy.

[22]  V. Leblond,et al.  Systemic infections withTrichosporon beigelii (cutaneum). Report of three new cases , 1986 .

[23]  G. Bodey,et al.  Trichosporon beigelii infection: a review. , 1986, Reviews of infectious diseases.

[24]  T. Walsh,et al.  Trichosporonosis in Patients with Neoplastic Disease , 1986, Medicine.

[25]  A. Schaffner,et al.  The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. , 1985, The Journal of infectious diseases.

[26]  K. Watson,et al.  Brain abscess due to Trichosporon cutaneum. , 1970, Journal of medical microbiology.